GLP-1 Market
LLY $1157.49 ▲ +1.3% NVO $37.53 ▼ -0.0% PFE $27.50 ▲ +0.3% VKTX $28.38 ▼ -3.1% KLRA $10.83 ▼ -0.1% GPCR $27.47 ▼ -0.4% RHHBY $52.55 ▲ +0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

gut-brain axis (GLP-1)-activating food carbohydrate

Company
Indiana University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 7, 2026

Trial details
  • Not yet recruiting NCT NCT07823452

    Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity

    Not yet reported Indiana University 62 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: gut-brain axis (GLP-1)-activating food carbohydrate, GLP-1-activating carbohydrate

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.